Awards & Advancement

Stundick joins Spero Therapeutics

Friday, January 22, 2016

Spero Therapeutics, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, has announced the appointment of Melissa Stundick, Ph.D., to the newly created leadership position of head of Strategic Alliances.

[Read More]

Recipharm appoints new key account director for Europe

Wednesday, January 20, 2016

Recipharm has appointed Anke Mollowitz to the role of key account director. Mollowitz has joined the business management team and is responsible for coordinating customer management and commercial aspects, as well as developing relationships with a selected number of customers in Europe.

[Read More]

Halloran Consulting Group adds CMO Mark Weinberg

Tuesday, January 12, 2016

Halloran Consulting Group has expanded its strategic capabilities with the addition of Mark Weinberg, M.D., MBA, who will serve as chief medical officer (CMO) and managing director. The addition of Weinberg to Halloran’s advisory services creates a unique offering to life sciences companies seeking CMO expertise as a key part of an on-demand, integrated development team.

[Read More]

Celgene announces exec changes, including Hugan and executive chairman

Tuesday, January 12, 2016

Celgene has announced organizational changes that will position the company for continued long-term growth, effective March 1. Bob Hugin will serve as executive chairman. Hugin will continue to lead the board of directors and manage the strategic direction of the company. Mark Alles will be promoted to chief executive officer. Jacqualyn Fouse, Ph.D., will be promoted to president and chief operating officer. Scott Smith, president of immunology and inflammation, will assume an expanded leadership role.

[Read More]

Aegerion appoints Mary Szela CEO

Monday, January 11, 2016

Aegerion Pharmaceuticals, a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, has appointed Mary Szela as chief executive officer and a member of Aegerion’s board of directors. Szela brings 27 years of progressive leadership experience to Aegerion as well as valuable expertise building global billion-dollar brands, such as Humira, and advancing pipeline products in the biotechnology and pharmaceutical industries.

[Read More]

Valeant names Schiller Interim CEO

Thursday, January 7, 2016

Valeant Pharmaceuticals International has appointed Howard Schiller interim chief executive officer of Valeant, effective immediately. Schiller was Valeant’s chief financial officer from December 2011 through June 2015 and currently serves on Valeant’s board of directors. Valeant also announced that Robert Ingram, lead independent director, will serve as interim chairman of the board of directors.

[Read More]